BRPI0918139A2 - composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso - Google Patents

composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso

Info

Publication number
BRPI0918139A2
BRPI0918139A2 BRPI0918139A BRPI0918139A BRPI0918139A2 BR PI0918139 A2 BRPI0918139 A2 BR PI0918139A2 BR PI0918139 A BRPI0918139 A BR PI0918139A BR PI0918139 A BRPI0918139 A BR PI0918139A BR PI0918139 A2 BRPI0918139 A2 BR PI0918139A2
Authority
BR
Brazil
Prior art keywords
dietary
medicinal
treatment
composition
functional food
Prior art date
Application number
BRPI0918139A
Other languages
English (en)
Inventor
Guy M Miller
Viktoria Kheifets
Original Assignee
Edison Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Pharmaceuticals Inc filed Critical Edison Pharmaceuticals Inc
Publication of BRPI0918139A2 publication Critical patent/BRPI0918139A2/pt
Publication of BRPI0918139B1 publication Critical patent/BRPI0918139B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/08Dihydroxy benzenes; Alkylated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00Quinones
    • C07C50/02Quinones with monocyclic quinoid structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00Quinones
    • C07C50/02Quinones with monocyclic quinoid structure
    • C07C50/06Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pediatric Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0918139-3A 2008-09-10 2009-09-08 Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos BRPI0918139B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19169608P 2008-09-10 2008-09-10
US61/191,696 2008-09-10
PCT/US2009/056254 WO2010030607A1 (en) 2008-09-10 2009-09-08 Treatment of pervasive developmental disorders with redox-active therapeutics

Publications (2)

Publication Number Publication Date
BRPI0918139A2 true BRPI0918139A2 (pt) 2015-12-01
BRPI0918139B1 BRPI0918139B1 (pt) 2024-04-30

Family

ID=41226405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918139-3A BRPI0918139B1 (pt) 2008-09-10 2009-09-08 Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos

Country Status (8)

Country Link
US (7) US8314153B2 (pt)
EP (2) EP3827815B1 (pt)
JP (6) JP2012502064A (pt)
BR (1) BRPI0918139B1 (pt)
CA (1) CA2736250C (pt)
LT (1) LT3827815T (pt)
MX (2) MX2011002318A (pt)
WO (1) WO2010030607A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
ES2714900T3 (es) * 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US8952071B2 (en) * 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
DK2362875T3 (en) 2008-10-28 2015-11-30 Edison Pharmaceuticals Inc METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
CN102647981B (zh) * 2009-08-26 2016-09-28 爱迪生制药有限公司 预防和治疗脑缺血的方法
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
MY183449A (en) * 2010-04-27 2021-02-18 Bioelectron Tech Corp Formulations of quinones for the treatment of ophthalmic diseases
US8828453B2 (en) * 2010-04-29 2014-09-09 Betul Hatipoglu Herbal-based compositions for alleviating symptoms associated with autism
JP6045494B2 (ja) * 2010-08-06 2016-12-14 エジソン ファーマシューティカルズ, インコーポレイテッド ナフトキノンによるミトコンドリア病の処置
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
US9162957B2 (en) 2011-07-19 2015-10-20 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CA2853945C (en) * 2011-10-31 2020-09-22 The Johns Hopkins University Methods and compositions for treatment of autism
US9629815B2 (en) 2012-09-07 2017-04-25 Bioelectron Technology Corporation Benzoquinone derivatives for treating oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
CN113365616A (zh) 2018-10-17 2021-09-07 Ptc医疗公司 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CA3156499A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Inc. CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
WO2021077034A1 (en) 2019-10-18 2021-04-22 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물
WO2024050725A1 (en) 2022-09-07 2024-03-14 Ptc Therapeutics, Inc. Methods of producing 2, 3, 5, 6-alkyl-1, 4-benzoquinones

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856414A (en) 1958-10-14 Oxidation of alpha-tocopherol
FR5531E (fr) 1905-03-02 1906-05-02 Gaston Levy Lajeunesse Perfectionnements aux moteurs à explosions
US2398418A (en) 1943-08-27 1946-04-16 Louis F Fieser Introduction of organic radicals into quinones
FR1201200A (fr) 1958-08-08 1959-12-29 Sogespar S A Procédé de fabrication de l'alpha tocophéryl-quinone
US3071512A (en) 1959-01-26 1963-01-01 Sogespar S A New hypotensive pharmaceutical preparation containing alpha-tocopheryl-quinone
US3406188A (en) 1964-03-27 1968-10-15 Sun Oil Co Preparation of alpha-tocopherylquinone
FR5531M (pt) 1966-02-08 1967-11-13
FR1536576A (fr) 1967-08-29 1968-08-16 Eastman Kodak Co Procédés d'enrichissement et de fractionnement de mélanges à base de tocophérols
US3728363A (en) 1970-03-17 1973-04-17 Takeda Chemical Industries Ltd Quinone derivatives
US3705239A (en) 1970-10-16 1972-12-05 Roy B Gregory Pain removing compositions and methods
UST917001I4 (en) 1971-12-02 1973-12-04 Defensive publication
JPS4875564A (pt) 1972-01-08 1973-10-11
JPS4988862A (pt) 1972-12-29 1974-08-24
JPS5245698B2 (pt) 1973-04-06 1977-11-17
DE2431198A1 (de) 1973-07-02 1975-01-23 Takeda Chemical Industries Ltd Chinonderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittelzubereitungen
US3909376A (en) 1974-12-04 1975-09-30 Basf Ag Electrolytic manufacture of alkyl-substituted hydroquinones
JPS52111576A (en) 1976-03-15 1977-09-19 Teijin Ltd Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol
JPS5938203B2 (ja) 1976-04-26 1984-09-14 エーザイ株式会社 補酵素qを主成分とする脳循環障害治療剤
LU77344A1 (pt) 1977-05-16 1979-01-19
US4153614A (en) 1978-05-12 1979-05-08 Hoffmann-La Roche Inc. Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein
US4201879A (en) 1977-05-16 1980-05-06 Hoffmann-La Roche Inc. Hydroquinones
US4310465A (en) * 1977-05-17 1982-01-12 Hoffmann-La Roche Inc. Synthesis of vitamin E and quinone intermediates
US4127608A (en) 1977-05-17 1978-11-28 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4201726A (en) 1977-05-17 1980-05-06 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4243598A (en) 1977-05-17 1981-01-06 Hoffmann-La Roche Inc. Synthesis of vitamin E
US4185154A (en) 1977-05-17 1980-01-22 Hoffmann-La Roche, Inc. Synthesis of vitamin E
JPS5640651A (en) 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS56147746A (en) 1980-04-15 1981-11-16 Takeda Chem Ind Ltd Quinones and their preparation
JPS567734A (en) 1979-06-28 1981-01-27 Takeda Chem Ind Ltd Preparation of quinone derivative
JPS567737A (en) 1979-07-02 1981-01-27 Takeda Chem Ind Ltd Physiologically active quinone and its preparation
JPS5697223A (en) 1979-12-30 1981-08-05 Takeda Chem Ind Ltd Tissue metabolism activator
JPS56140943U (pt) 1980-03-19 1981-10-24
JPS56140943A (en) 1980-04-07 1981-11-04 Takeda Chem Ind Ltd Preparation of organic compound
JPH0193554A (ja) 1980-04-07 1989-04-12 Takeda Chem Ind Ltd 有機化合物
US4393075A (en) 1980-04-14 1983-07-12 Takeda Chemical Industries, Ltd. Quinone compounds and their use in suppressing the production of SRS-A in mammals
JPS5750935Y2 (pt) 1980-06-03 1982-11-06
JPS5750935A (en) 1980-09-12 1982-03-25 Otsuka Pharmaceut Co Ltd 1,4-benzoquinone derivative
JPS57131735A (en) 1981-02-09 1982-08-14 Takeda Chem Ind Ltd Preparation of quinones
JPS6140236Y2 (pt) 1981-04-03 1986-11-17
JPS57183782A (en) 1981-04-30 1982-11-12 Sumitomo Chem Co Ltd Preparation of coumarone compound
JPS5818374A (ja) 1981-07-27 1983-02-02 Nitsusui Seiyaku Kk エイコサペンタエン酸トコフエロ−ルエステル
JPS5883698A (ja) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd キノン化合物およびその製造法
JPS5883698U (ja) 1981-11-27 1983-06-06 石川島播磨重工業株式会社 熱交換器
JPS6028919Y2 (ja) 1981-12-28 1985-09-02 松下電器産業株式会社 太陽熱集熱装置
JPS58193689A (ja) 1982-05-10 1983-11-11 Shiseido Co Ltd テストステロン−5α−レダクタ−ゼ阻害剤
JPS58193689U (ja) 1982-06-18 1983-12-23 三菱電機株式会社 電子部材実装装置
DK449983A (da) 1982-10-27 1984-04-28 Hoffmann La Roche Fremgangsmaade til fremstilling af optiske aktive forbindelser
CH655005A5 (it) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
JPS59163316A (ja) 1983-03-08 1984-09-14 Eisai Co Ltd けいれんの治療・予防剤
JPS6028919A (ja) 1983-07-28 1985-02-14 Shiseido Co Ltd 皮膚外用剤
EP0134198A1 (de) 1983-08-10 1985-03-13 Ciba-Geigy Ag Verwendung von Chinonderivaten zum Schützen von Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden
JPS60197621A (ja) 1984-03-19 1985-10-07 Hohnen Oil Co Ltd コレステロ−ル低下剤
MX9203040A (es) 1984-08-01 1992-07-31 Takeda Chemical Industries Ltd Derivados de quinona y composicion farmaceutica que los contiene.
US5304658A (en) 1984-08-01 1994-04-19 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
US4592867A (en) 1984-10-19 1986-06-03 Energy Conversion Devices, Inc. Synthesis method for reductant precursor
US4617317A (en) 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
EP0183869B1 (en) 1984-12-06 1991-04-17 Kuraray Co., Ltd. Chroman compounds and their use
JPH0511467Y2 (pt) 1985-03-19 1993-03-22
US5229385A (en) 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5057514A (en) 1987-02-03 1991-10-15 Suntory Limited Compounds effective as cerebral schemia treating agents
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5179092A (en) 1987-12-22 1993-01-12 Suntory Limited Compound effective as cerebral insufficiency improver
US5292768A (en) 1987-12-22 1994-03-08 Suntory Limited Compound effective as cerebral insufficiency improver
DK36389A (da) 1988-02-05 1989-08-06 Eastman Kodak Co Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion
JPH01209445A (ja) 1988-02-17 1989-08-23 Fuji Photo Film Co Ltd 放射線感応性材料
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
JPH029875A (ja) 1988-03-16 1990-01-12 Bio Ind Kyokai トコフェロール及びトコトリエノールの製造方法
DE3818696C1 (en) 1988-06-01 1989-03-30 Ems-Inventa Ag, Zuerich, Ch Process for the preparation of hydroquinone and its alkyl derivatives
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
JPH08768B2 (ja) 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
FI102273B (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
JP3086284B2 (ja) 1991-07-05 2000-09-11 京セラミタ株式会社 電子写真感光体
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
EP0543417A1 (en) 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
EP0560568A3 (en) 1992-03-13 1994-06-29 Takeda Chemical Industries Ltd Hydroquinone derivatives and intermediates for production thereof
US5981601A (en) 1992-05-28 1999-11-09 Centre For Molecular Biology And Medicine Method for enhancing cellular bioenergy
CN1093360A (zh) 1992-10-02 1994-10-12 武田药品工业株式会社 2-o-烷基抗坏血酸的锂盐
DE69420776T2 (de) 1993-06-18 2000-05-18 Takeda Chemical Industries Ltd Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
US5600029A (en) 1994-03-09 1997-02-04 Takeda Chemical Industries, Ltd. Process for producing DL-tocopherols and intermediates therefor
CN1129400A (zh) 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
US6133278A (en) 1994-08-12 2000-10-17 Takeda Chemical Industries, Ltd. Use of quinone and hydroquinone derivatives for the treatment of cachexia
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
JPH0892151A (ja) 1994-09-29 1996-04-09 Sagami Chem Res Center アリルキノンの製造方法
US5547827A (en) 1994-12-22 1996-08-20 Eastman Kodak Company Iodochloride emulsions containing quinones having high sensitivity and low fog
EP0719552A3 (en) 1994-12-26 1997-08-20 Takeda Chemical Industries Ltd Pharmaceutical composition containing a quinone derivative or the hydroquinone thereof for the treatment of dermatitis
KR100264348B1 (ko) 1994-12-28 2000-08-16 디르크 반테 항-죽종형성제로서 네비볼롤을 함유하는 조성물
US20030134028A1 (en) 1995-06-01 2003-07-17 Lipton, Division Of Conopco, Inc. Fat based food products
EP0846109B1 (en) 1995-08-21 2002-07-24 Takeda Chemical Industries, Ltd. Quinone compound, its production and use
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
PT842165E (pt) 1996-03-25 2001-08-30 Alcon Laboratoires Inc Derivados de acido tiazolidina-4-carboxilico como agentes citoprotectores
WO1998002149A2 (en) 1996-07-11 1998-01-22 Takeda Chemical Industries, Ltd. Use of idebenone and analogues against beta amyloid induced cytotoxicity
FR2753098B1 (fr) 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
GB9702310D0 (en) 1997-02-05 1997-03-26 Univ Hertfordshire Invention
GB9722361D0 (en) 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
AU746369B2 (en) 1997-11-17 2002-04-18 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
EP1051411B1 (en) 1998-01-29 2002-08-28 Eastman Chemical Company Methods for separating a tocol from a tocol-containing mixture
US5969133A (en) 1998-05-22 1999-10-19 Shiongi Bioresearch Corp. Bioreductive cytotoxic agents
US6433199B1 (en) 1998-05-22 2002-08-13 Shionogi Bioresearch Corporation Quinone derivatives
KR20010072080A (ko) 1998-07-31 2001-07-31 쓰끼하시 다미까따 페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6187811B1 (en) 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6562372B1 (en) 1998-11-06 2003-05-13 Fuji Chemical Industry Co., Ltd. Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
JP2000202297A (ja) 1999-01-20 2000-07-25 Chemiprokasei Kaisha Ltd 新規な酸化反応用触媒およびそれを用いたp―ベンゾキノン類の製造方法
NZ513926A (en) 1999-02-23 2001-09-28 Univ California Methods of treatment of mitochondrial disorders
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE19916801A1 (de) 1999-04-14 2000-11-02 Bosch Gmbh Robert Spritzdüse für eine Scheibenwaschanlage
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US6346544B2 (en) 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
WO2001092215A2 (en) 2000-06-02 2001-12-06 Us Health Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
DE10034233A1 (de) 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US6545184B1 (en) 2000-08-15 2003-04-08 The Regents Of The University Of California Practical, cost-effective synthesis of COQ10
US20030206972A1 (en) 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
WO2002034259A1 (en) 2000-10-26 2002-05-02 Fournier Laboratories Ireland Limited Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
WO2002043507A2 (en) 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
US6764768B2 (en) 2001-02-28 2004-07-20 Arch Development Corporation Controlled release composition
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
JP2003064017A (ja) 2001-06-12 2003-03-05 Hokko Chem Ind Co Ltd オキシスチレン誘導体の蒸留方法
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
AU2002327517B2 (en) 2001-08-21 2008-04-17 Johnson & Johnson Consumer Companies, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
CA2357053A1 (en) 2001-09-04 2003-03-04 Unknown Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease
JP2003137716A (ja) 2001-10-30 2003-05-14 Eau De Faveur:Kk 皮膚の外用剤
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US7217133B2 (en) * 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
AT414082B (de) * 2002-05-03 2006-09-15 Vis Vitalis Lizenz & Handels Verfahren zur herstellung von tocotrienol-angereicherten präparationen
US7327800B2 (en) 2002-05-24 2008-02-05 Vecima Networks Inc. System and method for data detection in wireless communication systems
ATE328283T1 (de) 2002-07-01 2006-06-15 Santhera Pharmaceuticals Ch Screeningverfahren und verbindungen zur behandlung von friedreich ataxia
US6953331B2 (en) 2002-08-30 2005-10-11 Extreme Components L.P. Positioning device with bearing mechanism
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ, インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
US20070135335A1 (en) 2003-02-10 2007-06-14 Autogen Research Pty Ltd. Therapeutic molecules
RU2006101991A (ru) 2003-06-25 2006-06-27 Чарлз ЭРВИН (US) Химическая композиция и способ увеличения подачи кофермента q10
KR20060113651A (ko) 2003-08-08 2006-11-02 더 오하이오 스테이트 유니버시티 리서치 파운데이션 토코트리에놀의 보호 용도 및 치료 용도
BRPI0413742B8 (pt) 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
US7118688B2 (en) 2004-02-23 2006-10-10 The Texas A&M University System Antioxidant compositions and methods of use thereof
US7022441B2 (en) 2004-02-25 2006-04-04 Eastman Kodak Company Silver-free black-and-white thermographic materials containing a benzoquinone and methods of imaging
WO2005084660A1 (ja) * 2004-03-05 2005-09-15 Morishige, Fumie ミトコンドリア病予防と対策
JP5129563B2 (ja) 2004-03-18 2013-01-30 ラスク・インテレクチュアル・リザーブ・アクチェンゲゼルシャフト 視神経症に対する感受性を診断または予測するための方法
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
WO2005115478A2 (en) * 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
US8116262B2 (en) 2004-06-22 2012-02-14 Rockstar Bidco Lp Methods and systems for enabling feedback in wireless communication networks
DE102004032837A1 (de) 2004-07-02 2006-02-09 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
KR101270841B1 (ko) 2005-02-28 2013-06-05 가부시키가이샤 메이지 히드로퀴논 장쇄 유도체 및/또는 페녹시 장쇄 유도체 및 이들을 함유하는 의약
EP1885353B1 (en) 2005-04-22 2015-01-07 Elizabeth Stuart Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
TW200744458A (en) 2005-06-30 2007-12-16 Kyowa Chem Ind Co Ltd Antibacterial agent composed of silver-containing aluminum sulfate hydroxide particles and use thereof
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP1924292A2 (en) 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US20070208086A1 (en) 2006-02-15 2007-09-06 The Regents Of The University Of California Ubiquinone analogs and methods of use
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ, インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
JPWO2007116750A1 (ja) 2006-03-30 2009-08-20 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びこれを用いた有機エレクトロルミネッセンス素子
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
CN101610782A (zh) 2007-01-10 2009-12-23 爱迪生药物公司 使用具有***或血小板生成素活性的化合物治疗呼吸链紊乱
ES2732293T3 (es) * 2007-02-22 2019-11-21 Childrens Hospital & Res Center At Oakland Formulaciones de ácidos grasos y métodos para el uso de las mismas
MY162051A (en) 2007-05-24 2017-05-31 Loders Croklaan Bv Process for producing compositions comprising tocopherols and tocotrienols
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2710253A1 (en) 2008-01-07 2009-07-16 Centocor Ortho Biotech Inc. Method of treating erythropoietin hyporesponsive anemias
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
JP5710277B2 (ja) * 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ, インコーポレイテッド 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体
US20110046156A1 (en) 2008-03-05 2011-02-24 Miller Guy M Treatment of hearing and balance impairments with redox-active therapeutics
CA2723621A1 (en) 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
JP5731980B2 (ja) 2008-10-09 2015-06-10 ラムズコア, インコーポレイテッド ドライアイ症候群の処置のための組成物および方法
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
DK2362875T3 (en) 2008-10-28 2015-11-30 Edison Pharmaceuticals Inc METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES
US20100273892A1 (en) 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
WO2010126910A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
CN102647981B (zh) 2009-08-26 2016-09-28 爱迪生制药有限公司 预防和治疗脑缺血的方法
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
US20110172312A1 (en) 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
US20110263720A1 (en) 2010-03-09 2011-10-27 Penwest Pharmaceuticals Co. Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
EA201201374A1 (ru) 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
MY183449A (en) 2010-04-27 2021-02-18 Bioelectron Tech Corp Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
WO2012019032A1 (en) 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
JP6045494B2 (ja) 2010-08-06 2016-12-14 エジソン ファーマシューティカルズ, インコーポレイテッド ナフトキノンによるミトコンドリア病の処置
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
US20150057363A1 (en) 2011-07-06 2015-02-26 Guy M. Miller Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
US9162957B2 (en) 2011-07-19 2015-10-20 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US9629815B2 (en) 2012-09-07 2017-04-25 Bioelectron Technology Corporation Benzoquinone derivatives for treating oxidative stress disorders
JP6313791B2 (ja) 2013-03-08 2018-04-18 ユニリーバー・ナームローゼ・ベンノートシヤープ 皮膚科学的使用のためのレゾルシノール化合物
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP3004071A1 (en) 2013-05-31 2016-04-13 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018081644A1 (en) 2016-10-28 2018-05-03 Bioelectron Technology Corporation Methods of analyzing p-hydroquinone levels and ratios

Also Published As

Publication number Publication date
US20190083419A1 (en) 2019-03-21
EP2344142A1 (en) 2011-07-20
CA2736250A1 (en) 2010-03-18
US10736857B2 (en) 2020-08-11
JP2018162281A (ja) 2018-10-18
WO2010030607A1 (en) 2010-03-18
JP2017122125A (ja) 2017-07-13
MX363223B (es) 2019-03-15
JP2016020399A (ja) 2016-02-04
BRPI0918139B1 (pt) 2024-04-30
JP6259410B2 (ja) 2018-01-10
EP3827815B1 (en) 2023-09-06
CA2736250C (en) 2016-12-20
US8314153B2 (en) 2012-11-20
LT3827815T (lt) 2023-10-10
US9399612B2 (en) 2016-07-26
US20170157065A1 (en) 2017-06-08
US8653144B2 (en) 2014-02-18
US20140206772A1 (en) 2014-07-24
US20130053450A1 (en) 2013-02-28
MX2011002318A (es) 2011-05-10
US20100063161A1 (en) 2010-03-11
US20150239818A1 (en) 2015-08-27
US10105325B2 (en) 2018-10-23
US8969420B2 (en) 2015-03-03
JP2015110674A (ja) 2015-06-18
JP2015120748A (ja) 2015-07-02
US20210128494A1 (en) 2021-05-06
JP2012502064A (ja) 2012-01-26
EP3827815A1 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CR20150232A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
ZA201002989B (en) New antibodies specific of the beta-amyloid and their uses as diagnostic agents or drugs
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
HK1142536A1 (en) Gel useful for the delivery of cosmetic active ingredients
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
BRPI0817974A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
BRPI0916043A2 (pt) composição farmacêutica e alimento funcional para prevenir ou tratar câncer
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
ZA201104079B (en) Therapeutic,dietary,or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3,and compositions containing these compounds
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BRPI0913839A2 (pt) composição farmacêutica com glicosaminoglicanos e uso da mesma no tratamento de úlceras crônicas
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
BRPI0722057A2 (pt) Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.
ZA201005875B (en) Use of interleukin-1 conjugates in the treatment of diabetes
BRPI0813937A2 (pt) Derivado de 17beta-ciano-19-nor-andros-4-eno, seu uso e medicamentos contendo o derivado

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: PTC THERAPEUTICS, INC. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.